在患有前乳腺瘤的患者中取消多巴胺激动剂
Stefan Matei Constantinescu1, Orsalia Alexopoulou1, Dominique Maiter1
1Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Brussels 1200, Belgium.
Best practice & research. Clinical endocrinology & metabolism
|February 15, 2026
概括
多巴胺激动剂有效治疗乳腺癌,但有副作用. 本综述探讨了最佳的多巴胺激动剂戒断策略,并讨论了监测和复发管理.
科学领域:
- 内分泌学 在内分泌学.
- 神经药理学神经药理学
- 在瘤学瘤学.
背景情况:
- 多巴胺激动剂 (DA) 是对益生菌瘤的第一线治疗,使益生菌素正常化,恢复淋巴腺功能,并缩小瘤.
- 慢性DA治疗存在挑战,包括短期副作用 (恶心,头),冲动控制障碍和心脏监测需求.
- 利益和风险的平衡促使考虑减少和停止DA治疗.
研究的目的:
- 对不同患者群体 (绝经前/绝经后妇女,男性,儿童/青少年) 审查和定义最佳的多巴胺激素抑制剂戒断策略.
- 概述了戒药后的监测协议和对前乳腺瘤复发的管理策略.
- 确定了解治疗耐药性和实现长期缓解的研究需求.
主要方法:
- 对多巴胺激素抑制剂治疗和前乳腺瘤中戒断的现有证据的系统审查.
- 分析临床数据以确定有效和安全的戒断方案.
- 讨论当前的监测和复发管理实践.
主要成果:
- 多巴胺激动剂提供了显著的好处,但携带风险,需要谨慎管理.
- 根据患者人口统计学量身定制的具体戒断策略至关重要.
- 有效的监测和复发管理计划对于长期患者护理至关重要.
结论:
- 优化多巴胺激动剂的戒断需要基于患者特征的个性化策略.
- 需要进一步的研究,以了解治疗耐药性背后的机制,并实现长期缓解在益生菌瘤患者.
相关概念视频
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.4K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
933
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
933
Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Drug Therapy
315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
315


